L-arginine
DrugOral L-arginine 2 g twice a day for 14 weeks
NCT Number: NCT00974714
The purpose of this study is to evaluate the effects of oral L-arginine administration on pregnant women at second trimester of gestation with chronic hypertension, respect with placebo.
Looking for future studies?
Notify Me18 year–40 year
Female
Interventional
Phase 3
University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral L-arginine 2 g twice a day for 14 weeks
oral placebo 2 g twice a day for 14 weeks
Time frame: 14 weeks
Time frame: 14 weeks
University of Modena and Reggio Emilia
Other
Effects of Oral L-arginine on Chronic Hypertension in Pregnancy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05852054
Cardiovascular Diseases, Diabetes Mellitus
Chicago, Illinois, United States
View Trial DetailsNCT05473767
Body Weight, Cardiovascular Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07074548
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
View Trial DetailsNCT05049616
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial Details